Lecithin cholesterol acyltransferase: an anti- or pro-atherogenic factor?
Curr Atheroscler Rep
; 13(3): 249-56, 2011 Jun.
Article
em En
| MEDLINE
| ID: mdl-21331766
ABSTRACT
Lecithin cholesterol acyl transferase (LCAT) is a plasma enzyme that esterifies cholesterol and raises high-density lipoprotein cholesterol, but its role in atherosclerosis is not clearly established. Studies of various animal models have yielded conflicting results, but studies done in rabbits and non-human primates, which more closely simulate human lipoprotein metabolism, indicate that LCAT is likely atheroprotective. Although suggestive, there are also no biomarker studies that mechanistically link LCAT with cardiovascular disease. Imaging studies of patients with LCAT deficiency have also not yielded a clear answer to the role of LCAT in atherosclerosis. Recombinant LCAT, however, is currently being developed as a therapeutic product for enzyme replacement therapy of patients with genetic disorders of LCAT for the prevention and/or treatment of renal disease, but it may also have value for the treatment of acute coronary syndrome.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Aterosclerose
/
Metabolismo dos Lipídeos
/
Fosfatidilcolina-Esterol O-Aciltransferase
/
Deficiência da Lecitina Colesterol Aciltransferase
/
HDL-Colesterol
Tipo de estudo:
Prognostic_studies
Idioma:
En
Revista:
Curr Atheroscler Rep
Ano de publicação:
2011
Tipo de documento:
Article
País de afiliação:
Estados Unidos